| Treatment group |  |  |
---|---|---|---|
 | Ivermectin only | 4 weeks doxycycline + ivermectin | 6 weeks doxycycline + ivermectin |
Mf-positives/persons examined | 11/11 | 7/7 | 4/4 |
% of mf-positive patients | 100 % | 100 % | 100 % |
GM before doxycycline treatment | 11.4 | 7.6 | 11.8 |
% of pre-treatment GM | 100 % | 100 % | 100 % |
Mf-positives/persons examined | 11/11 | 7/7 | 4/4 |
% of mf-positive patients | 100 % | 100 % | 100 % |
GM* when ivermectin was administered | 6.2 | 3.8 | 2.5 |
% of pre-treatment GM | 54.4 % | 50.0 % | 21.2 % |
Mf-positives/persons examined | 0/11 | 0/7 | 0/4 |
% of mf-positive patients | 0 % | 0 % | 0 % |
GM at 2 months ** | 0 | 0 | 0 |
% of pre-treatment GM | 0 % | 0 % | 0 % |
Mf-positives/persons examined | 8/11 | 1/7 | 0/4 |
% of mf-positive patients | 72.7 % | 14.3 % | 0 % |
GM at 12 months ** | 1.2 | 0.02 | 0 |
% of pre-treatment GM | 10.8 % | 0.3 % | 0 % |